Our unique approach
From harnessing innovative ideas, to translating concepts to therapies, to advancing treatments to people living with ALS – The ALS Association’s collaborative and global approach to funding research continues to lead to significant discoveries by top ALS scientists around the world.
Expediting the discovery of treatments and a cure
With the world’s largest ALS research program, The ALS Association is active in more than 150 labs around the globe. Meet the scientists and view an interactive map to learn more about the projects that your support makes possible!
Scientific focus areas critical to ALS research
Biomarkers. Nanotechnology. Disease mechanisms. Precision medicine. Drug development and more. The ALS Association supports a wide breadth of specific fields of study that are critical to advancing ALS research.
Championing patient care
People living with ALS are at the center of everything we do, and must receive the best care and support possible until there's a cure.
Driving research progress three unique ways
Maximizing investments
We secure matching gifts to double and even triple your investment in research.
Learn MoreAttracting bright young scientists
We provide fellowship grants to keep the best scientists focused on ALS throughout their careers.
Learn MoreInspiring partnerships
We drive collaboration among non-profits, academia, industry and government.
Learn MoreBringing the world's ALS scientists together
Scientific review panels
Don Cleveland, Ph.D.
University of California at San Diego, Elected Member, National Academy of Sciences
Richard G. Ellenbogen, MD, FACS
Professor, University of Washington, Seattle
Strategic meetings
Fred Gage, Ph.D.
Adler Professor, Laboratory of Genetics, The Salk Institute, La Jolla, Calif.
Global collaborations
Sabrina Paganoni, M.D.
Assistant Professor at Harvard Medical School, Cambridge, Mass.
Ammar Al-Chalabi, M.D.
Professor of Neurology and Complex Genetics, King’s College London
Merit Cudkowicz, M.D., MSc
Director of Massachusetts General Hospital (MGH) MDA ALS Clinic, Boston
Frank Walsh, Ph.D.
Founder and CEO, Ossianix Inc., University City Science Center, Philadelphia, Pa.
Shared data & samples
Jane Huggins, Ph.D.
Research Assistant Professor, University of Michigan, Ann Arbor, Mich.
Lawrence and Isabel Barnett Drug Development Program
Our Lawrence and Isabel Barnett Drug Development Program allows us the freedom to strategically fund preclinical projects aimed at developing therapeutics for ALS that are product-driven. It is anticipated that the agents and/or data generated from these funded projects will lead to the advancement of new therapies for ALS.
